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Summary: Our study will determine the prevalence, incidence, risk factors, and 
clinical outcomes of acute sarcopenia according to the revised European consensus on 
definition and diagnosis (EWGSOP2). 
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Research letter 1 
Sarcopenia in acute care patients: Protocol for the European Collaboration of Geriatric 2 
Surveys: Sarcopenia EAMA9+ project 3 
To the Editor: 4 
Sarcopenia is a disease characterized by a progressive loss of skeletal muscle mass and 5 
strength, and related to physical impairment, disability, worse clinical outcomes and mortality 6 
in all healthcare settings (1). Importantly it is also reversible, with tailored exercise and 7 
nutritional support (1)(2). Sarcopenia prevalence varies widely depending on the criteria, 8 
measurement methods, and cut-off points used for its assessment (1)(2); to date few studies 9 
addressed the issue of sarcopenia in hospitalized older patients, rendering it an under-10 
recognized clinical entity (3)(4). In 2015 the European Geriatric Medicine Society (EuGMS) 11 
founded the Special Interest Group on Sarcopenia, which aims to bridge the gaps between 12 
clinical practice and research (“Action-Research Philosophy”) by promoting collaborations 13 
between international scientific societies and institutions, and launching, in 2018, the revised 14 
European consensus on the definition and diagnosis on sarcopenia (EWGSOP2) (1).  15 
We aim to prospectively evaluate the prevalence and incidence of sarcopenia (as defined by 16 
the EWGSOP2 criteria) in hospitalized patients across Europe (Belgium, Denmark, Germany, 17 
Italy, the Czech Republic, Poland, Portugal, Spain, and the United Kingdom), to assess risk 18 
factors associated with its presence or incidence, and to assess sarcopenia-related adverse 19 
clinical outcomes. 20 
Study participants are patients aged >70 years admitted to acute medical units. Exclusion 21 
criteria are anticipated length of hospital stay <24 hours, and inability to perform the hand-22 
grip test. Each study partner will collect data for first 100 consecutive patients meeting the 23 
entry criteria. By including 900 participants we will be able to detect 10% incidence of 24 
*Manuscript
Click here to view linked References
2 
 
sarcopenia with an error of approximately 2% (the exact 95% confidence interval ranging 25 
from 8.04 to 11.96%).   26 
Primary outcomes include:  1) Prevalence of sarcopenia on admission (±48h) and 2) 27 
Incidence of sarcopenia between admission (±48h) and discharge (±24h). Secondary 28 
outcomes are: 1) Risk factors for the development of sarcopenia 2) In-hospital sarcopenia 29 
associated adverse outcomes (incidence of hospital-acquired infections, falls, delirium, 30 
length-of-stay, and mortality), and 3) Post-discharge adverse outcomes (institutionalization, 31 
hospital readmissions, falls, disability, and mortality) at 3- and 12-month follow-up. 32 
The new EWGSOP2 sarcopenia diagnostic criteria will be followed (1)(6)(7). These include, 33 
assessment of muscle strength with isometric hand-grip test (cut-off points <27kg, men; 34 
<16kg, women) (1); gait speed (4-m walk, <0.8m/s) (1), and calf-circumference (<31cm) (1). 35 
The SARC-F questionnaire (8) will be used on admission, 3- and 12-month telephone follow-36 
up. We will assess malnutrition (Global Leadership Initiative on Malnutrition (GLIM) 37 
criteria) (9)(10), physical frailty (FRAIL scale, Fried phenotype), functional status (Barthel’s, 38 
basic (ADL), and instrumental (IADL) activities of daily living), and cognition (Mini-Mental 39 
State Examination, Confusion Assessment Method, Geriatric Depression Scale).  40 
The study was registered in ClinicalTrials.gov (2018/8355/I) and is being approved by local 41 
ethics committees. Data will be treated in accordance with the General Data Protection 42 
Regulation of the European Parliament and Council (GDPR 2016/679).  43 
Conclusions and implications: The overall goal is to establish an epidemiological base for 44 
future geriatric research in Europe, in the previously largely overlooked area of sarcopenia in 45 
older hospitalized patients. Sarcopenia increases with age, especially after the age of 80 years, 46 
due to accumulation of both age-dependent and independent risk factors. Inflammaging, 47 
inactivity, and malnutrition may play particularly significant roles (1). Sarcopenia can be 48 
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prevented, and when developed can be a target for therapeutic actions. However, at present, 49 
there is limited knowledge of its prevalence and incidence in a real-world hospital population. 50 
The new EWGSOP2 guidelines offer a pragmatic approach which is more applicable to 51 
patients in an acute medical setting, and we intend to establish prevalence and incidence data, 52 
as well as important insights into risk factors for sarcopenia. We foresee that our results will 53 
have crucial implications for future research, clinical practice, and policies for optimal aging. 54 
Funding source: This research is not receiving any commercial sponsorship. 55 
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 Recruitment 
• Soon after hospital admission 
• Consent to participate and access notes for completion of demographics, blood test results & complications 
Admission 
assessment 
• Within 48 hours of admission 
• Questionnaires to include Barthel, SARC-F, mini-mental state examination...  
• Hand grip strength, gait speed (4 metres) and postural blood pressure if able, calf circumference 
Discharge 
assessment 
 
• Within 24 hours of discharge 
• Repeat Barthel, hand grip strength, gait speed (4 metres), calf circumference 
• Incidence of complications (falls, infections..) 
 
3 month 
follow-up 
 
• 3 months post-discharge - telephone follow-up 
• Repeat SARC-F & Barthel questionnaires 
• Information on complications (hospital readmission, institutionalization…) 
 
12 month 
follow-up 
• 12 months post-discharge - telephone follow-up 
• Repeat SARC-F & Barthel questionnaires 
• Information on complications (hospital readmission, institutionalization…) 
Figure
  
Supplementary Material
Click here to download Supplementary Material: Methods appendix_European Collaboration EAMA Sarcopenia 9+ _jg_svh.docx
